However, in aged 3xTg-AD mice with advanced Abeta and tau pathologies, reduction of soluble Abeta alone did not improve the cognitive phenotype, while reduction of both soluble Abeta and soluble tau ameliorated cognitive deficit [64]. This evidence concerns the gene MAPT and Alzheimer disease.